

NIVOLUMAB: CLINICAL EXPERIENCE IN A TERTIARY HOSPITAL

Gutiérrez Lorenzo M, Alcaraz Sánchez JJ, Mora Rodríguez B, Muñoz Castillo I.

Hospital Pharmacy Service. Hospital Regional Universitario de Málaga, Avenida Carlos Haya S/N

4CPS-099

Background

Nivolumab is approved in Spain for the treatment of patients with melanoma, metastatic non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), and has been included in our hospital's formulary since 2016.

Purpose

To evaluate the effectiveness and safety of patients treated with nivolumab in our hospital.

Material and methods

To evaluate the effectiveness and safety of patients treated with nivolumab in our hospital. Retrospective observational study of all patients treated with nivolumab **from February 2016 to June 2017**.

Data collected Clinical history	Age	ECOG	Prior lines treatment	% death
	Sex	Treatment duration	PFS and OS (Kaplan-Meier)	% adverse effects
	Diagnosis	Number of cycles	% patients continuing treatment	

Results



AGE
64,4 (39-99)
years
Median age

	Melanoma	NSCLC	RCC		Melanoma	NSCLC	RCC
Nº patients	20	20	1	(%) patients continuing treatment	20	35	0
Median disease stage	4	4	4	(%) deaths	40	45	0
Median ECOG	1	1	0	Median PFS (95% CI) (days)	74 (38-86)	76 (41-87)	No progression
Mean treatment duration (days)	118	129	70	Median OS (95% CI) (days)	96 (45-120)	99 (67-126)	No death
Median nº (cycles)	8,4	9,2	5				
Line: nº patients	First line: 12 Second-third line: 8	Second-third line: 20	Second line: 1				

63,4% patients
→ Toxicity grade I-II

- 24% **asthenia**
- 14,6% **pruritus and dermatological reactions**
- 9,7% **arthralgia or myalgia**
- 15,1% **others**

No patient required hospitalisation, however, 1 patient discontinued treatment for renal toxicity. Grade 3-4 reactions were not detected.

Conclusions

The effectiveness in terms of PFS and OS was more reduced than clinical essays, although we should consider that there were patients with ECOG ≥2. In most cases, nivolumab was safe and well tolerated. To evaluate efficacy and long term safety, a longer monitoring period is required.